Cullinan Competitors

CGEM Stock  USD 8.79  0.13  1.46%   
Cullinan Oncology LLC competes with Merck, Pfizer, Eli Lilly, Bristol Myers, and Johnson Johnson; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Cullinan Oncology competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Cullinan Oncology to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Cullinan Oncology Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Cullinan Oncology competition on your existing holdings.
  
As of the 15th of March 2025, Return On Tangible Assets is likely to drop to -0.3. In addition to that, Return On Capital Employed is likely to grow to -0.36. At this time, Cullinan Oncology's Total Assets are very stable compared to the past year. As of the 15th of March 2025, Other Current Assets is likely to grow to about 16.5 M, while Debt To Assets are likely to drop 0.
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Cullinan Oncology's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
5.318.7112.11
Details
Intrinsic
Valuation
LowRealHigh
7.9114.5817.98
Details
10 Analysts
Consensus
LowTargetHigh
30.0333.0036.63
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-1.01-0.83-0.73
Details

Cullinan Oncology Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Cullinan Oncology and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Cullinan and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Cullinan Oncology LLC does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
AMGNJNJ
GILDJNJ
GILDAMGN
JNJLLY
AMGNLLY
GILDLLY
  
High negative correlations   
LLYMRK
AMGNMRK
JNJMRK
GILDMRK

Risk-Adjusted Indicators

There is a big difference between Cullinan Stock performing well and Cullinan Oncology Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Cullinan Oncology's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

Cross Equities Net Income Analysis

Compare Cullinan Oncology LLC and related stocks such as Merck Company, Pfizer Inc, and Eli Lilly Net Income Over Time
Select Fundamental
Price To Sales RatioPtb Ratio
Days Sales OutstandingBook Value Per Share
Free Cash Flow YieldInvested Capital
Operating Cash Flow Per ShareAverage Payables
Stock Based Compensation To RevenueCapex To Depreciation
Pb RatioEv To Sales
Free Cash Flow Per ShareInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Sales General And Administrative To RevenueAverage Inventory
Research And Ddevelopement To RevenueCapex To Revenue
Cash Per SharePocfratio
Interest CoveragePayout Ratio
Capex To Operating Cash FlowPfcf Ratio
Days Payables OutstandingNet Current Asset Value
Income QualityTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Ev To Free Cash FlowIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Shareholders Equity Per ShareDebt To Equity
Capex Per ShareGraham Net Net
Average ReceivablesRevenue Per Share
Interest Debt Per ShareDebt To Assets
Enterprise Value Over E B I T D ADividend Yield
RoicPayables Turnover
RoeReturn On Tangible Assets
Earnings YieldGraham Number
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Debt Equity RatioEbit Per Revenue
Quick RatioDividend Paid And Capex Coverage Ratio
Net Income Per E B TCash Ratio
Cash Conversion CycleOperating Cash Flow Sales Ratio
Days Of Inventory OutstandingDays Of Sales Outstanding
Free Cash Flow Operating Cash Flow RatioCash Flow Coverage Ratios
Price To Book RatioCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Capital EmployedFixed Asset Turnover
Return On AssetsAsset Turnover
Return On Equity
2010201120122013201420152016201720182019202020212022202320242025
MRK539.9 M6.3 B6.7 B4.4 B11.9 B4.4 B5.7 B2.6 B6.2 B9.8 B7.1 B13 B14.5 B365 M17.1 B18 B
PFE579.7 M10 B14.6 B22 B9.1 BB7.2 B21.3 B11.2 B16.3 BB22 B31.4 B2.1 BB8.4 B
LLY517.6 M4.3 B4.1 B4.7 B2.4 B2.4 B2.7 B(204.1 M)3.2 B4.6 B6.2 B5.6 B6.2 B5.2 B10.6 B11.1 B
BMY1.1 B3.7 BB2.6 BB1.6 B4.5 BBB3.4 B(9 B)B6.3 BB(8.9 B)(8.5 B)
JNJ613.7 M9.7 B10.9 B13.8 B16.3 B15.4 B16.5 B1.3 B15.3 B15.1 B14.7 B20.9 B17.9 B35.2 B14.1 B9.6 B
AMGN500 K3.7 B4.3 B5.1 B5.2 B6.9 B7.7 BB8.4 B7.8 B7.3 B5.9 B6.6 B6.7 B4.1 B3.2 B
GILD(4 M)2.8 B2.6 B3.1 B12.1 B18.1 B13.5 B4.6 B5.5 B5.4 B89 M6.2 B4.6 B5.7 B480 M456 M

Cullinan Oncology LLC and related stocks such as Merck Company, Pfizer Inc, and Eli Lilly Net Income description

Net income is one of the most important fundamental items in finance. It plays a large role in Cullinan Oncology LLC financial statement analysis. It represents the amount of money remaining after all of Cullinan Oncology LLC operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Cullinan Oncology Competitive Analysis

The better you understand Cullinan Oncology competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Cullinan Oncology's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Cullinan Oncology's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
CGEM MRK PFE LLY BMY JNJ AMGN GILD
 1.46 
 8.79 
Cullinan
 0.15 
 94.57 
Merck
 0.47 
 25.72 
Pfizer
 1.48 
 813.48 
Eli
 2.11 
 59.01 
Bristol
 0.11 
 162.81 
Johnson
 0.34 
 313.71 
Amgen
 1.00 
 111.44 
Gilead
Market Volatility
(90 Days Market Risk)
Market Performance
(90 Days Performance)
Odds of Financial Distress
(Probability Of Bankruptcy)
Current Valuation
(Equity Enterprise Value)
Buy or Sell Advice
(Average Analysts Consensus)
Trade Advice
(90 Days Macroaxis Advice)
Current Ratio
Net Asset
Profit Margin
EBITDA
Current Valuation
Price To Book
Operating Margin
Retained Earnings
Current Asset
Five Year Return
Beta
Number Of Employees
Shares Outstanding
Cash Flow From Operations
Annual Yield
Total Debt
Return On Equity
Return On Asset
Number Of Shares Shorted
Book Value Per Share
Current Liabilities
Total Asset
Debt To Equity
Short Ratio
Target Price
Last Dividend Paid
Shares Owned By Institutions
Market Capitalization
Price To Earning
Price To Earnings To Growth
Price To Sales
Net Income
Earnings Per Share
Shares Owned By Insiders
Revenue
Working Capital
Cash And Equivalents
Cash Per Share
Gross Profit
Day Typical Price
Accumulation Distribution
Daily Balance Of Power
Period Momentum Indicator
Rate Of Daily Change
Day Median Price
Price Action Indicator
Coefficient Of Variation
Mean Deviation
Jensen Alpha
Total Risk Alpha
Sortino Ratio
Downside Variance
Standard Deviation
Kurtosis
Potential Upside
Treynor Ratio
Maximum Drawdown
Variance
Market Risk Adjusted Performance
Risk Adjusted Performance
Skewness
Semi Deviation
Information Ratio
Value At Risk
Expected Short fall
Downside Deviation
Semi Variance

Cullinan Oncology Competition Performance Charts

Five steps to successful analysis of Cullinan Oncology Competition

Cullinan Oncology's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Cullinan Oncology LLC in relation to its competition. Cullinan Oncology's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Cullinan Oncology in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Cullinan Oncology's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Cullinan Oncology LLC, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Cullinan Oncology position

In addition to having Cullinan Oncology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Healthcare Funds Thematic Idea Now

Healthcare Funds
Healthcare Funds Theme
Funds or Etfs investing in medical and healthcare goods or services as well as hospital management or maintenance organizations. The Healthcare Funds theme has 26 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Healthcare Funds Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Cullinan Oncology LLC is a strong investment it is important to analyze Cullinan Oncology's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cullinan Oncology's future performance. For an informed investment choice regarding Cullinan Stock, refer to the following important reports:
Check out Cullinan Oncology Correlation with its peers.
You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cullinan Oncology. If investors know Cullinan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cullinan Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.78)
Return On Assets
(0.22)
Return On Equity
(0.32)
The market value of Cullinan Oncology LLC is measured differently than its book value, which is the value of Cullinan that is recorded on the company's balance sheet. Investors also form their own opinion of Cullinan Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cullinan Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cullinan Oncology's market value can be influenced by many factors that don't directly affect Cullinan Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cullinan Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cullinan Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cullinan Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.